Read More Pharma Industry News This diabetes breakthrough drug slashes risk by 94%—discover how tirzepatide is transforming obesity treatment Eli Lilly and Company (NYSE: LLY) has released compelling results from the SURMOUNT-1 study, which highlights that tirzepatide… byPallavi MadhirajuAugust 20, 2024